Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Nobel Laureate Dr. Louis J. Ignarro Joins the Angiogenesis Foundation's Advisory Board


News provided by

The Angiogenesis Foundation

Aug 26, 2026, 13:43 ET

Share this article

Share toX

Share this article

Share toX

Dr. Ignarro, whose groundbreaking discoveries established nitric oxide as a critical signaling molecule in cardiovascular health, will advise the Foundation on vascular science, disease prevention, and the effects of diet and lifestyle on circulation. His appointment coincides with the August 25 release of the fully revised and updated edition of NO More Heart Disease (St. Martin's Press).

World-renowned scientist whose discoveries revealed the role of nitric oxide in cardiovascular health will support the Foundation's work in vascular science, disease prevention, and public education

CAMBRIDGE, Mass., Aug. 26, 2026 /PRNewswire-PRWeb/ -- The Angiogenesis Foundation announced today that Nobel Laureate Louis J. Ignarro, PhD, has joined its distinguished Advisory Board. Dr. Ignarro, whose groundbreaking research established nitric oxide (NO) as a critical signaling molecule in the cardiovascular system, will advise the Foundation as it advances its mission to help people live healthier, longer lives through angiogenesis-based science, treatment, and prevention.

Dr. Ignarro's expertise in nitric oxide and vascular biology closely complements the Foundation's leadership in angiogenesis, the process by which the body grows and maintains blood vessels. As an advisor, he will also provide scientific guidance on the effects of diet and lifestyle on nitric oxide and its effects on the circulation.

"We are very honored to welcome Dr. Lou Ignarro to the Angiogenesis Foundation's Advisory Board," said William W. Li, MD, CEO, President and Medical Director of the Angiogenesis Foundation. "His discoveries fundamentally changed our understanding of how blood vessels function. Nitric oxide and angiogenesis are deeply interconnected when it comes to vascular health. Dr. Ignarro brings extraordinary insights into the role of NO in health and disease prevention."

"I am delighted to join the Angiogenesis Foundation as an advisor," said Dr. Ignarro. "Dr. Li and the Foundation have been working to translate modern medicine by bringing vascular science to fruition in ways that improve people's lives. I look forward to contributing my knowledge to advance the Foundation's work, especially in extending healthspan and lifespan."

Dr. Ignarro began his academic research into nitric oxide and cyclic GMP at Tulane University School of Medicine before joining the UCLA School of Medicine in 1985. He later became Distinguished Professor of Pharmacology and is now professor emeritus in UCLA's Department of Molecular and Medical Pharmacology.

In 1998, Dr. Ignarro shared the Nobel Prize in Physiology or Medicine with Robert F. Furchgott and Ferid Murad for their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system. His research helped reveal how nitric oxide relaxes vascular smooth muscle, mediates the effects of nitroglycerin, and supports essential cardiovascular functions.

Dr. Ignarro is the founder of the Nitric Oxide Society and a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society. His many honors include the American Heart Association's Basic Research Prize and Distinguished Scientist Award, the CIBA Award for Hypertension Research, and the Golden Plate Award for his contributions to cardiovascular research.

His appointment to the Angiogenesis Foundation's Advisory Board coincides with the August 25 release of the fully revised and updated edition of NO More Heart Disease (St. Martin's Press). In the book, Dr. Ignarro explains the science of nitric oxide and offers readers practical guidance for supporting cardiovascular health and longevity.

The Foundation will feature Dr. Ignarro in upcoming educational content examining nitric oxide, angiogenesis, circulation, and vascular health.

About the Angiogenesis Foundation

The Angiogenesis Foundation is an independent 501(c)(3) nonprofit scientific organization driving innovation in health promotion, disease prevention, and treatments based on vascular health. Founded in 1994 and based in Cambridge, Massachusetts, the Foundation advances health and medicine by focusing on angiogenesis, the process the body uses to grow blood vessels.

The Foundation takes a systems-based approach to connect, analyze, and translate scientific discoveries into better health outcomes for people around the world. Its mission is to help people live healthier, longer lives through angiogenesis-based treatment and prevention.

To learn more about the Angiogenesis Foundation, visit www.angio.org, and follow @theangiogenesisfoundation on Instagram, Facebook, and YouTube.

Media Contact

Ashley Sandberg, The Angiogenesis Foundation, 1 3477356480, [email protected], www.angio.org

SOURCE The Angiogenesis Foundation

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.